Clinical Trial Update: RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC [Phase 2]

View source ↗

Summary

Phase 2 trial investigating RP2 and RP3 in combination with atezolizumab and bevacizumab for refractory metastatic colorectal cancer with pMMR/MSS has been term…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)
• Bevacizumab (bevacizumab)
• RP2
• RP3

Snippet

Sponsor: Replimune, Inc. | Conditions: Refractory Metastatic Colorectal Cancer, pMMR | Phase 2 | Status: TERMINATED